|
|
Article: GlycoGenesys, Inc. Achieves Primary Objective in Phase I Trial in Advanced Solid Tumors Preliminary Response Data on 14 Patients Shows 11 Achieve Stable Disease.
- Article from:
- Business Wire
- Article date:
- September 8, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOSTON -- GlycoGenesys, Inc., (NASDAQ: GLGS), a biotechnology company focused on carbohydrate-based drug development, provided an update on its ongoing Phase I trial evaluating GCS-100 in patients with solid tumors.
SUMMARY
Today the Company announced preliminary results from its ongoing Phase I clinical trial in advanced solid tumors:
--Establishing a maximum tolerated dose for GCS-100 under the protocol;
--Showing of the 14 patients for which response data is available, 11 have experienced periods of stable disease; and
--Providing safety and pharmacokinetic data that supports the Company's bloodborne cancer programs.
...